Although two Nampt inhibitors have entered clinical trials, no attempt was made to select potentially responsive patients in these trials. Tumor-specific loss of NAPRT1 is synthetically lethal with co-administration of a NAMPT inhibitor and NA.
Results
Nicotinate phosphoribosyltransferase (NAPRT1) is necessary for NA rescue and its expression is the major determinant of rescue status. We demonstrate that NAPRT1 promoter methylation accounts for NAPRT1 deficiency in cancer cells, and NAPRT1 methylation is predictive of rescue status in cancer cell lines. Bisulfite NGS mapping of the NAPRT1 promoter identified tumor specific sites of NAPRT1 DNA methylation and enabled development of a quantitative methylation specific PCR (QMSP) assay suitable for use on archival formalin fixed paraffin embedded tumor tissue.
Conclusions
Tumor-specific promoter hyper-methylation of NAPRT1 inactivates one of two NAD salvage pathways, resulting in synthetic lethality with the co-administration of a NAMPT inhibitor. NAPRT1 expression is lost due to promoter hyper-methylation in most cancer types evaluated at frequencies ranging from 5 to 65%. NAPRT1-specific IHC or DNA methylation assays can be used on archival formalin paraffin embedded cancer tissue to identify patients likely to benefit from co-administration of a Nampt inhibitor and NA.
Introduction
There has been a recent re-awakening of interest in targeting the altered metabolic state of cancer cells to combat cancer. Although the observation that cancer cells utilize atypical metabolic pathways was originally made quite some time ago (1) , it was unclear how to exploit this property for cancer therapeutics development.
However, there are now a number of inhibitors of metabolic enzymes and a wealth of cancer genome data that is opening new avenues to target cancer metabolism (2) .
One approach is to inhibit NAD biosynthesis (3) . Cancer cells appear to require higher levels of NAD and NADH because they have high metabolic demands and rely heavily on glycolysis, a process that is far less efficient than oxidative phosphorylation for generating ATP. In addition, cancer cells may require more NAD due to increased activity of NAD consuming enzymes such as the sirtuins and poly-ADP ribose polymerases (PARPS) (4) .
Nicotinamide phosphoribosyltransferase (NAMPT), also known as visfatin or pre-Bcell colony-enhancing factor (PBEF), catalyzes the rate-limiting step in the primary salvage pathway used to generate NAD. It transfers a phosphoribosyl residue from 5-phosphoribosyl-1-pyrophosphate (PRPP) to nicotinamide (NAM) to produce nicotinamide mononucleotide (NMN), which is subsequently converted into NAD+ by nicotinomide mononucleotide adenylyl transferase (NMNAT) (5) (6) (7) . Three NAMPT inhibitors of two distinct structural classes have entered clinical trials for cancer, APO866 (formerly FK866) (8) , GMX1778 (formerly CHS828) and a pro-drug of GMX1778, GMX1777 (9) (10) (11) . In these trials, thrombocytopenia and gastrointestinal toxicity were the most common adverse events, with thrombocytopenia being the dose limiting toxicity (12) (13) (14) . Author Manuscript Published OnlineFirst on October 4, 2013; DOI: 10.1158/1078-0432.CCR- which is converted to NAD by NMNAT ( Figure 1A ). Addition of NA to the media or food allows this pathway to generate sufficient levels of NAD to mitigate the cytotoxic effects of a NAMPT inhibitor in cultured cells and animal rodents (15) (16) (17) as well as in human megakaryocyte (18) . Interestingly, some cancers do not express NAPRT1 (19) , rendering this pathway non-functional. Therefore, supplementation with NA has the potential to mitigate the toxicity of NAMPT inhibitors to normal tissues that express NAPRT1, but not in NAPRT1 deficient cancer cells, thereby increasing the potential therapeutic index of NAMPT inhibitors. Although this strategy has been described and tested in animal models, there was no attempt to select patients based on NAPRT1 status or co-administer NA in clinical trials of NAMPT inhibitors. Thus, the strategy of selecting patients with NAPRT1 deficient tumors and co-administering NA remains untested in the clinic.
To enable clinical implementation of this novel diagnostic strategy, we sought to identify the mechanism by which functional NAPRT1 is lost, determine the frequency of NAPRT1 deficiency across a large number of indications, and develop assays to identify NAPRT1 deficient cancers in patients 
Materials and Methods

Cellular and Biochemical Assays
LC-MS Assay for NAD Concentration
The concentration of NAD in cells was determined by a non-validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay using 13 C 5 -NAD as an internal standard (IS). Detailed methods are in the supplement.
Immunohistochemistry
Immunohistochemistry (IHC) for NAPRT1 was performed on a Ventana Discovery XT autostainer (Ventana Medical Systems, Tucson, AZ). Formalin-fixed, paraffinembedded whole tissue and tissue microarray sections were deparaffinized and pretreated with CC1 solution (Ventana Medical Systems) for 60 mins followed by incubation with either 0.5 ug/ml NAPRT1 rabbit polyclonal antibody (Novus 
RNA-seq and Copy Number Analysis
RNA-seq reads were aligned to the human genome version GRCh37 using GSNAP (20) . Gene expression was obtained by counting the number of reads aligning concordantly within a pair and uniquely to each gene locus as defined by CCDS. The gene counts were then normalized using the DESeq Bioconductor software package (21) . Illumina HumanOmni2.5_4v1 arrays were used to assay 906 cancer cell lines for genotype, DNA copy and LOH at ~2.2 million SNP positions following methods published previously (PMID:23033341 and PMID:22895193). Copy number for NAPRT1 was calculated as the average absolute copy number for all SNPs within or directly adjacent to the bounds of the genomic region covered by any RefSeq transcript for that gene. Samples with a copy number < 2 were counted as having a deletion. previously described (23) . For NGS sequencing, DNA samples containing equal amounts of 8 bisulfite PCR products (~500 ng DNA total) were treated with T4 DNA polymerase, Klenow large fragment, and T4 polynucleotide kinase to generate 5'-phosphorylated blunt ends. After concatemerization with T4 DNA ligase the sample was sonicated to an average fragment length of 150-300 bp using a Misonix cuphorn sonicator 3000. Libraries were generated from these sonicated DNA samples using the standard Illumina protocol. The 24 samples were indexed with 7-bp barcodes (independent Illumina index read). Sequencing on Hi-Seq generated a total of 115 million 50-nt reads. Reads were aligned to the reference sequence using the bismark software (24) . As reference sequence, either the PCR amplified target region (in NAPRT1 gene promoter) or the entire chr8 (hg19) was used. Alignments were captured in SAM/BAM files, and percentage methylation at each CpG site was determined by running the appropriate bismark scripts. Read coverage at each CpG site was determined by generating a signal map at 1-bp resolution (using Active Motif software), and individual 50-nt reads with specific methylation status were counted using a combination of samtools (25) and standard UNIX commands. Gene schematic generated with FancyGene.
DNA Methylation Analysis
For QMSP assays sodium bisulfite converted DNA was amplified using previously described conditions (23) .
Results
Evaluation of Rescue Identifies Cancer Types that May Benefit from Coadministration of NAMPT Inhibitor and Nicotinic Acid
GNE-617 is a novel small molecule inhibitor of NAMPT (Fig S1A) that inhibits the biochemical activity of NAMPT with an IC 50 of 5nM and exhibits efficacy in xenograft models of cancer (26) . As expected, this molecule causes rapid depletion of cellular NAD followed by a decrease in ATP (Fig S1B) . We evaluated the activity of GNE-617 (Fig 1B) , and we refer to these as "non-rescuable" cell lines. The majority of the cell lines tested have IC 50 values below 100nM, with approximately half with IC 50 values less than 10nM. We find a significant correlation between baseline expression of NAMPT and IC 50 , consistent with previous reports (16) , and between NAPRT1 expression and IC 50 (Table S1 ).
Eighteen cell lines were not rescued with NA, and these non-rescuable cell lines tended to have lower IC 50 values (p=0.008, Fishers exact test, IC 50 < 10nM versus >10nM) (Fig 1C) .
To explore the prevalence of the NA rescue phenotype across indications, we evaluated a panel of cancer cell lines for response to 10uM GNE-617 in the presence or absence of 10uM NA and find 16% (72/445) are not rescued with NA (Table S2) .
Cell lines derived from brain tumors or sarcomas exhibit the non-rescuable phenotype at a higher frequency than other types of cancer cell lines (45% and 67%, respectively), consistent with previous reports (16) . In this study, we expand into a larger variety of cancer types and find at least one non-rescuable cell line from most indications tested. However, with the exception of sarcomas and brain tumors, the prevalence is less than 35% ( Figure 1D ).
Rescue of NAMPT Inhibitor Toxicity by NA is Due to NAPRT1 Deficiency
Previous studies have indicated that NAPRT1 is required for NA rescue (16, 17) . We wanted to test this observation in a larger panel of cell lines and identify additional determinants of NA rescue across cancer cell lines from a diverse range of tissue types. We evaluated the cell line panel shown in Figure 1D for correlation between gene expression and NA rescue. The best correlate of the rescue phenotype is NAPRT1 (adjusted p= 6 x10 -30 (Figure 2A-B) . To demonstrate that NAPRT1 is necessary for NA rescue, we reduced the level of NAPRT1 by siRNA in A549 cells.
NAPRT1 reduction did not change the IC50 for GNE-617, but the cells were no longer rescued with NA. To demonstrate that NAPRT1 is sufficient for rescue, we expressed NAPRT1 in the NAPRT1 deficient RERF-LC-MS cell line and observed NA rescue in this line compared to the same line transfected with the empty vector control, which remains non-rescuable ( Figure 2C ).
In the 32 cell lines for which we had NAPRT1 protein quantification and gene expression data, there was a strong correlation between mRNA and protein (Spearman R=0.88, p <10 -4 ) ( Figure S1C ). In light of these data, we evaluated a panel of 551 cancer cell lines for NAPRT1 deficiency by gene expression to identify additional cancer types with and models that are likely to be non-rescuable ( Figure   2D , Table S3 ). We set the threshold for NAPRT1 deficiency based on gene expression levels that allow NA rescue in the NSCLC cell line panel. The threshold selected, 7.2, is close to the lower limit of detection on the Affymetrix array ( Figure   S1C ), suggesting little or no gene expression. The most well represented indications, lung and breast cancer exhibited NAPRT1 deficiency at rates of 17% and 10%, respectively, similar to percentages of non-rescuable lines shown in figure 1D .
There were no sarcoma cell lines in this panel, and the prevalence of NAPRT1 deficiency in gliomas, 9%, was lower than expected. Liver cancer cell lines had the highest prevalence of NAPRT1 deficiency (45%), slightly higher than the observation of 31% in the previous panel. This panel contains more lymphoma lines and these exhibited the second highest rate of NAPRT1 deficiency (38%), consistent with observations made on lymphoma tissue (19) . In summary, lymphomas, sarcomas and hepatocellular carcinomas tend to have higher rates of NAPRT1 deficiency.
Research. 
IHC Can be Used to Identify NAPRT1 Deficient Tumors
We next developed an immunohistochemical (IHC) assay for NAPRT1 using cell lines with known levels of NAPRT1 to validate the method. NAPRT1 staining on NSCLC tissue is cytoplasmic and has a large dynamic range. Benign cells stained with an intensity of IHC 1+, whereas malignant cells stained across the full range of IHC scores (0 -3+) ( Figure 3A) . In order to determine the level of NAPRT1 necessary for NA rescue, we generated a cell pellet microarray from NCSLC cell lines with known rescue status and scored them for NAPRT1 on a scale of 0 to 3. With only one exception, cell lines with IHC scores greater than zero were rescued by NA ( Figure 3B ). We next stained tumor samples from a variety of tumor types and determined the fraction with NAPRT1 IHC scores of zero ( Figure 3C ). Small cell lung cancer (SCLC) had a high prevalence of NAPRT1 deficiency (60%), but it should be noted that the number of samples was low (n=10). In general, the prevalence of IHC 0 by tumor type was consistent with the prevalence of NAPRT1 deficiency and loss of NA rescue in the cell lines. Thus, an IHC assay could be used to select patients for co-administration of NAMPT inhibitor and NA. Based on these pre-clinical data, we propose that an IHC score of zero will be predictive of a tumor likely to respond to the combination of a NAMPT inhibitor and NA.
NAPRT1 is Methylated in a Subset of Lung, Pancreatic and Ovarian
Tumors
The finding that loss of NAPRT1 expression has a strong negative association with NA rescue suggested that NAPRT1 expression was completely absent in certain contexts. We examined copy number by SNP arrays in a panel of 906 cell lines and find that NAPRT1 underwent loss of heterozygosity (LOH) in 18.6% of cell lines. In addition, we found four cell lines with single copy deletion at the NAPRT1 locus (BJAB, HCC1428, COLO-824, and NCI-H1882). We next examined NAPRT1 copy number in tumor tissue from TCGA, and found the frequency of LOH to be 12.8% in ovarian cancer tissue (n=405), and between 4.3 and 6.5% across 2066 breast, colon, GBM, ovarian and squamous lung cancer samples. There was single copy deletion of Importantly, no methylation on the CpG island was detected in normal immortalized bronchial and small airway epithelial cells suggesting that the methylation we observed is tumor cell line specific. To demonstrate that hypermethylation of the NAPRT1 promoter causes transcriptional gene silencing, we treated 34 NSCLC cell lines with 5-aza-2'deoxycytidine (5-azadC). NAPRT1 expression was detectable both before and after 5-azadC treatment in cell lines that could be rescued by coadminstration of NA. In contrast, low or no expression of NAPRT1 could be detected in cell lines that could not be rescued by co-adminstration of NA before 5-azadC treatment, whereas after 5-azadC treatment NAPRT1 expression was comparable to rescuable cell lines ( Figure 4D ).
We next evaluated the correlation of NAPRT1 methylation and gene expression as measured by RNAseq ( Figure 5A ). As expected, the strongest relationship between expression and methylation was at the extreme ends of the range of beta values. Overall, there is strong correlation between expression and methylation in all three cell line panels, with a correlation coefficient of -0.69 (n=179) ( Figure 5A ). We then evaluated the correlation between methylation and expression in publically available data from TCGA for breast cancer and lung adenocarcinoma. We find a similar strong negative association between expression and methylation in these data with correlation coefficients of -0.513 (n=513) and -0.534 (n=232), in breast and lung cancer, respectively ( Figure 5B, C) . Next we evaluated the sensitivity and specificity of NAPRT1 methylation to predict NA rescue. Using beta values from the Infinium array, we calculated a positive predictive value of 1.0 (17/17), with a sensitivity of 0.94 (17/18) and specificity of 0.97 (34/35) ( Figure 5D ). Taken together, these data show that NAPRT1 expression is silenced by promoter hypermethylation in NSCLC and that promoter hypermethylation of NAPRT1 is inversely associated with NA rescue in cancer cell lines.
Bisulfite Next Generation Sequencing Identifies Tumor Specific
Methylation Sites in NAPRT1
Based on the strength of the association between NAPRT1 methylation, expression, and rescue we considered development of a quantitative methylation assay for use in clinical samples. We employed a next-generation bisulfite sequencing (NGBS) strategy to identify the most appropriate target region for quantitative methylation specific PCR (QMSP) assay development within the NAPRT1 CpG island. We Figure 6A ).
These data suggest that a well-designed QMSP assay should be able to distinguish between tumors with complete promoter methylation and background signal in the tissue sample. We tested the QMSP assay in cell lines with known methylation and NA rescue status. Consistent with bisulfite sequencing, QMSP distinguishes cell lines with methylation within the target region of the assay. Thus QMSP can be used to identify cell lines that lack NAPRT1 and are thus unable to be rescued by NA ( Figure   6B ).
Most tumor samples obtained in clinical trials are archival diagnostic biopsies or surgical resections. These samples are almost always formalin-fixed paraffin embedded slides or blocks. Thus, to enable a diagnostic hypothesis in the clinic a molecular assay needs to work well on these preserved tissue specimens. We tested the QMSP assay on tissue with known IHC status and we detected methylation only in the sample with IHC score of zero. Conversely, we did not detect any methylation in the tumor sample with an IHC score of 3+ ( Figure 6C ).
Discussion
Evaluation of NAPRT1 in cancer tissue provides the opportunity for a unique biomarker strategy for selection of patients likely to respond to NAMPT inhibitors. By evaluating NA rescue and gene expression in over 400 cancer cell lines, we confirm that NAPRT1 level is the major determinant of NA rescue status and define a threshold mRNA level below which NA rescue was not observed. However, this will be challenging to translate into a clinical assay because even small amounts of contaminating tissue could result in an incorrect conclusion that NAPRT1 is expressed. IHC allows cell level resolution of staining and discrimination of staining in malignant tissue compared to adjacent normal tissue. NAPRT1 has been evaluated by IHC in prior studies (16, 19) , but there was no determination of the required threshold for rescue. In this study, we evaluated a panel of NSCLC cell lines for NA rescue status in culture and prepared cell pellets for IHC from the same cells.
With this approach, we determined that an IHC score of zero correlated with lack of NA rescue. Determination of the threshold is essential for the implementation of NAPRT1 IHC as a diagnostic assay in solid tumor indications where there is a broad spectrum of NAPRT1 level.
We show that loss of function of the NAPRT1 gene is mediated primarily by hypermethylation of the CpG island that overlaps with the transcription start site of NAPRT1. Importantly, complete methylation of the CpG island is strongly associated with the absence of rescue in cell lines treated with GNE-617 and NA. Reduction of DNA methylation by treatment of cells with 5-aza-dC was sufficient to induce NAPRT1 expression in cell lines in which the locus was hyper-methylated. We mapped the sites of DNA methylation in non-rescuable cell lines using NGBS and used this high-resolution map to develop a methylation specific QMSP assay suitable for use on tissue preserved in FFPE slides. There are a several advantages to using a QMSP assay as a molecular diagnostic to identify patients. Pre-amplification allows detection of NAPRT1 methylation from very small amounts of tissue which could MGMT for dacarbazine (37) and BRCA1 for PARP inhibitors (38) (39) (40) , and this study adds an additional example. Both MGMT and BRCA1 are tumor suppressor genes.
The finding that NAPRT1 is subject to single copy deletion along with more frequent LOH and promoter hypermethylation suggests that NAPRT1 may act as a tumor suppressor gene in some contexts. It is not clear why loss of NAPRT1 expression would be advantageous to some cancers as the gene contributes to the NAD synthetic capacity of the cell. However, it is interesting to note that frequent hypermethylation of another metabolic enzyme, LDHB, has recently been reported in breast cancer (31) , suggesting that alteration of metabolic pathways by DNA methylation may be a more general phenomenon in cancer. -H1568  A-427  NCI-H2030  NCI-H23  RERF-LC-MS  NCI-H2405  NCI-H1650  NCI-H838  NCI-H1355  RERF-LC-OK  NCI-H520  VWRC-LCD  NCI-H1770  NCI-H2106  SK-MES-1  SW1573  NCI-H1703  EKVX  CALU-6  NCI-H1299  HCC2279  NCI-H1781  NCI-H1435  HOP-18  NCI-H292  HOP-62  NCI-H1975  NCI-H2126  A549  KNS-62  HCC827  NCI-H1563  UMC-11  EBC-1  HOP-92  NCI-H1838  NCI-H460  NCI-H1793  NCI-H650  NCI-H2122  NCI-H727  NCI-H1651  NCI-H226  NCI-H647  NCI- brain (31) uterine (6) liver (16) kidney (12) Research. 
